论文部分内容阅读
Ticarcillin(Ⅰ)是一个新的半合成青霉素,结构与 carbenicillin(Ⅱ)相似。(Ⅰ)的活性约为(Ⅱ)的两倍,两者有交叉耐药。Ⅰ具有广谱活性,特别是对绿脓杆菌、变形杆菌及一些肠道菌有作用。在临床上分离得到113株致病菌中,对绿脓杆菌的最低抑菌浓度为25微克/毫升,对奇异变形杆菌呈高度活性,其最低抑菌浓度为1～<0.25微克/毫升,对大肠杆菌的敏感性似呈双形型分布,推测其中的耐药菌株产生β-内酰胺酶。
Ticarcillin (Ⅰ) is a new semisynthetic penicillin whose structure is similar to that of carbenicillin (Ⅱ). (Ⅰ) activity of about (Ⅱ) twice, both cross-resistant. Ⅰ has a broad spectrum of activity, especially against Pseudomonas aeruginosa, Proteus and some intestinal bacteria. Of the 113 pathogenic bacteria clinically isolated, the minimum inhibitory concentration against Pseudomonas aeruginosa was 25 μg / ml, which was highly active against Proteus mirabilis with a minimum inhibitory concentration of 1 to <0.25 μg / ml, E. coli susceptibility appeared to be bimodal distribution, suggesting that the drug-resistant strains produce β-lactamase.